Open AccessTreatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib
Author(s) -
Joy A. Lee,
Pooja Magavi,
Gauree G. Konijeti
Publication year - 2020
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izaa158
Subject(s) - tofacitinib , vedolizumab , ulcerative colitis , medicine , inflammatory bowel disease , pouchitis , dermatology , gastroenterology , immunology , rheumatoid arthritis , disease
The case report describes the benefits of combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and seronegative inflammatory spondyloarthritis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom